BioCentury
ARTICLE | Company News

Allenex transplant, diagnostic news

February 11, 2013 8:00 AM UTC

Allenex received €215,000 ($292,293) as part of a €2.6 million ($3.6 million) award from the EU's Seventh Framework Program (FP7) to the EUROSTAM consortium of European Transplant Centers, which aims to enhance transplantation in patients with a high risk of genetic mismatches. The goal of the three-year project, which has an estimated cost of €3.6 million ($4.9 million), is to determine the clinical value and feasibility of implementing a Europe-wide human leukocyte antigen (HLA) mismatch program to facilitate safe transplantation in patients with rare HLA phenotypes. Under the project, Allenex's AbSorber AB subsidiary will a modified version of its XM-ONE endothelial crossmatch test kit to determine if antibodies are complement or non-complement fixing. AbSorber markets XM-ONE to identify patients at risk of antibody-mediated rejections prior to kidney transplantation. ...